Israel’s MyBiotics (see here previously) is to partner Hadasit – the technology transfer arm of Hadassah Medical Center, to identify gut microbiome-based cancer therapies. They will study up to 100 melanoma patients treated with PD-1/PD-L1 checkpoint inhibitor immunotherapies. https://www.timesofisrael.com/mybiotics-hadassah-to-study-impact-of-microbiome-on-cancer-therapies/

A Weizmann Institute-led international team of researchers has found how bacteria in the gut microbiome affects the body’s response to cancer immunotherapy (see also here previously). Also, patients treated with specific antibiotics had a poor response to CAR-T cancer treatment. … Continue reading →

Israel’s Biomica (see here previously) has given 12 cancer patients, who had poor responses to immunotherapy, pills containing bacteria missing from their gut microbiome. In 2020, doctors at Sheba hospital used fecal bacteria to shrink the tumors of three cancer … Continue reading →

As reported previously (see here) Israel’s Biomica is using the human microbiome (stomach bacteria) to fight cancer, IBD, acne etc. Bionica is starting pre-clinical studies for BMC321 & BMC322, two developed microbial consortia aimed to treat Inflammatory Bowel Disease (IBD). … Continue reading →

I reported previously (May 2017) on one Israeli biotech using the human microbiome (stomach bacteria) to fight cancer, IBD, acne etc. Now Israel’s Evogene’s new Biomica subsidiary is also developing microbiome therapies, for antibiotic resistant bacteria, immuno-oncology and GI disorders. … Continue reading →

Israeli biotech BiomX is developing a pipeline of treatments for unmet medical needs, including cancer, inflammatory bowel disease and acne.  BiomX focuses on modulating the human microbiome – bacteria that reside in and on the human body – to boost … Continue reading →